Last updated on June 2012

AAML1031, A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443) and Sorafenib (IND# 69896) for Patients with High Allelic Ratio FLT3/ITD


Brief description of study

AAML1031, A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443) and Sorafenib (IND# 69896) for Patients with High Allelic Ratio FLT3/ITD

Detailed Study Description

For more information please visit: http://clinicaltrials.gov/ct2/show/NCT01371981?term=AAML1031&rank=1

Clinical Study Identifier: TX136004

Contact Investigators or Research Sites near you

Start Over

Patricia Green

Memorial Health University Medical Center
Savannah, GA USA
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.